The Ward Study for SeptiCyte® Lab to Distinguish Between Infection-positive and Infection-negative SIRS



Status:Terminated
Conditions:Infectious Disease, Hospital
Therapuetic Areas:Immunology / Infectious Diseases, Other
Healthy:No
Age Range:18 - 89
Updated:4/17/2018
Start Date:June 2015
End Date:February 2018

Use our guide to learn which trials are right for you!

To Assess the Performance of SeptiCyte® Lab to Diagnose Patients Identified as Suspected of Sepsis in General Medical and Surgical Wards With Infection-positive From Infection-negative SIRS

A non-interventional, prospective observational study to assess the performance of SeptiCyte®
Lab to diagnose patients identified as suspected of sepsis in general medical and surgical
wards with infection-positive from infection-negative SIRS

This study is evaluating a molecular diagnostic device developed to distinguish between
sepsis and infection-negative SIRS among critically ill patients.

This study is a prospective, non-randomized, non-interventional, observational trial of
patients with suspected sepsis in the medical and/or surgical wards. The study is being
conducted on two preselected patient care units.

All patients identified by a local screening tool undergo physician review. If the suspicion
of sepsis is found to be plausible, routine and conventional diagnostic procedures,
including: routine bloods, blood culture and specialized tests are conducted.

Blood collection for SeptiCyte® Lab and SeptID® is drawn within 6 hours of a positive screen
- both use peripheral blood as the clinical sample. The diagnostic performance of the two
experimental assays will be compared to Retrospective Physician Diagnosis (RPD), and
conventional microbiological culture. The results of SeptiCyte® Lab and SeptID® are not used
in any clinical decision-making.

This data will be used to analyze the performance of SeptiCyte® Lab according to the endpoint
measures.

Inclusion Criteria:

1. 18-89 years old on the day of enrollment.

2. Currently admitted to study designated medical or surgical ward

3. Have a clinical suspicion of sepsis as determined by two physicians after
identification by hospital screening tool.

4. Screened positive for sepsis, severe sepsis or septic shock using the RISE2 screening
tool.

5. Completed SBAR handover (Situation, Background, Assessment, Recommendation)

6. SIRS present as defined by the presence of two or more of the following:

- Temperature > 38°C or < 36°C

- Heart Rate > 90 beat/min

- Tachypnea > 20/min or PaCO2 < 32 mmHg

- WBC count > 12 000/mm3 or < 4 000/mm3 or > 10% immature neutrophils (bands)

Exclusion Criteria:

1. Consent not provided

2. Patients less than 18 years of age, or 90 years of age or older.

3. Patients for which a blood sample could not be taken within 24 hours of a physician
first determining a clinical suspicion of sepsis.

4. Patients that are not located in the designated medical or surgical ward associated
with the study.

5. Patients listed for "Comfort Measures Only".

6. Less than 2 SIRS criteria

7. Commencement of narrow spectrum directed antibiotics prior to screening.
We found this trial at
1
site
593 Eddy Street
Providence, Rhode Island 02903
401-444-4000
Principal Investigator: Mitchell Levy, MD
Phone: 401-444-4961
Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, RI, is a private,...
?
mi
from
Providence, RI
Click here to add this to my saved trials